Virtual Evolution: A Conference for Women by Women
59 y/o Woman With HER2+ Invasive Ductal Carcinoma Who Received 6 Cycles of Neoadjuvant TCHP: Which Post-Neoadjuvant Systemic Option to Consider? What Are RT Options?
Login to view comments.
Click here to Login
